Sarepta Therapeutics
(SRPT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 613,077 | 510,598 | 240,867 | 1,103,010 | 197,855 |
| Marketable Securities | 237,916 | 289,541 | 281,895 | 251,782 | 1,000,534 |
| Receivables | 395,739 | 527,295 | 659,371 | 601,988 | 434,524 |
| Inventories | 1,077,166 | 994,036 | 941,432 | 749,960 | 565,924 |
| Other current assets | 398,411 | 335,515 | 308,968 | 366,723 | 486,532 |
| TOTAL | $2,722,309 | $2,656,985 | $2,432,533 | $3,073,463 | $2,685,369 |
| Non-Current Assets | |||||
| PPE Net | 358,936 | 371,857 | 360,587 | 340,336 | 305,788 |
| Investments And Advances | 1,040 | 230,126 | 263,495 | 133,163 | 181,770 |
| Other Non-Current Assets | 411,152 | 420,846 | 408,772 | 416,211 | 427,007 |
| TOTAL | $771,128 | $1,022,829 | $1,032,854 | $889,710 | $914,565 |
| Total Assets | $3,493,437 | $3,679,814 | $3,465,387 | $3,963,173 | $3,599,934 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 91,595 |
| Accounts payable and accrued liabilities | 94,015 | 136,702 | 156,105 | 214,442 | 118,774 |
| Accrued Expenses | 295,793 | 377,399 | 391,650 | 373,513 | 344,830 |
| Other current liabilities | 46,168 | 10,416 | 12,974 | 13,473 | 17,289 |
| TOTAL | $921,425 | $919,948 | $605,588 | $731,684 | $699,489 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,035,146 | 1,139,458 | 1,138,289 | 1,137,124 | 1,135,965 |
| Deferred Revenues | 485,449 | 395,431 | 44,859 | 130,256 | 127,001 |
| Other Non-Current Liabilities | 216,746 | 263,023 | 253,787 | 241,623 | 218,409 |
| TOTAL | $1,251,892 | $1,402,481 | $1,717,076 | $1,703,747 | $1,679,374 |
| Total Liabilities | $2,173,317 | $2,322,429 | $2,322,664 | $2,435,431 | $2,378,863 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 104,787 | 97,713 | 98,277 | 97,032 | 95,520 |
| Common Shares | 11 | 10 | 10 | 10 | 10 |
| Retained earnings | -4,641,537 | -4,461,590 | -4,658,482 | -4,210,974 | -4,370,023 |
| Other shareholders' equity | -43 | -314 | 34 | -218 | 2,245 |
| TOTAL | $1,320,120 | $1,357,385 | $1,142,723 | $1,527,742 | $1,221,071 |
| Total Liabilities And Equity | $3,493,437 | $3,679,814 | $3,465,387 | $3,963,173 | $3,599,934 |